Different from SCN1A LOF variants, SCN2A GOF variants can also cause Dravet syndrome, and oxcarbazepine treatment is usually effective (Zeng et al., 2022). Here, SCN2A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.